Dermatologists use novel combination therapy to restore skin color in vitiligo patients

2018

Doctors and dermatologists alike have searched for an effective treatment option for vitiligo. A recent study conducted by a team of Yale doctors may have found just that. Utilizing an off-label use of the arthritis medication, tofacitinib, and narrow band ultraviolet B light therapy has resulted in promising and positive patient outcomes. By experimenting with this combination of therapies in recent studies, patients have noticed total or close to total restoration of skin color in affected areas. There is still much to learn about this revolutionary treatment option; however, what is known so far is assuring.

Full Article

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Full Article Yiu Z, Ashcroft D, Evans I, McElhone K, Lunt M, Smith C, Walton S, Murphy R, Reynolds N, Ormerod A, Griffiths C, Warren

Moderate exercise and bright light treatment in overweight and obese individuals

Full Article Dunai A, Novak M, Chung S, Kayumov L, Keszei A, Levitan R, Shapiro C Obesity. 2007;15(7):1749-1757. “This randomized, controlled study is the first

Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study

Full Article Malanos D Stern R J Am Acad Dermatol. 2007;57(2):231-7. doi:10.1016/j.jaad.2007.04.027 A common fear associated with the use of psoralen plus ultraviolet A (PUVA)

Dermatologists use novel combination therapy to restore skin color in vitiligo patients

Other Articles

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Moderate exercise and bright light treatment in overweight and obese individuals

Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study

CALL 1-800-DAAVLIN OR FILL OUT THE FORM BELOW

CALL 1-800-DAAVLIN OR
FILL OUT THE FORM BELOW